Home » Stocks » MDXG

MiMedx Group, Inc. (MDXG)

Stock Price: $8.88 USD 0.06 (0.68%)
Updated Jan 22, 2021 4:00 PM EST - Market closed
Market Cap 983.86M
Revenue (ttm) 256.09M
Net Income (ttm) -72.75M
Shares Out 108.49M
EPS (ttm) -0.67
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 22
Last Price $8.88
Previous Close $8.82
Change ($) 0.06
Change (%) 0.68%
Day's Open 8.80
Day's Range 8.72 - 9.01
Day's Volume 322,438
52-Week Range 5.78 - 10.31

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Seeking Alpha - 4 weeks ago

Persistent and sustained institutional buying in MiMedx should not be ignored as heavy hitters position themselves for key knee osteoarthritis data in 2021. Sales and revenue growth after two ...

Seeking Alpha - 1 month ago

Significant evidence indicates that Amniofix is a highly effective and safe treatment for knee OA, and that the product will likely receive FDA approval for this indication. The RMAT designati...

GlobeNewsWire - 1 month ago

Experienced Healthcare Executive Will Expand Company's Visibility Within the Financial Community

GlobeNewsWire - 1 month ago

MARIETTA, Ga., Nov. 24, 2020 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MiMedx” or the “Company”), an industry leader in advanced wound care and a therapeutic biologics company, t...

Seeking Alpha - 2 months ago

MiMedx Group is in the early stages of a sales recovery, after a turbulent last 2 years. 90% of management are new faces, and the new growth strategy dovetails to include commercialization, R&...

GlobeNewsWire - 2 months ago

MARIETTA, Ga., Nov. 13, 2020 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ: MDXG) (“MiMedx” or the “Company”), an industry leader in advanced wound care and a therapeutic biologics company, t...

GlobeNewsWire - 2 months ago

MARIETTA, Ga., Nov. 12, 2020 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MiMedx” or the “Company”), an industry leader in advanced wound care and a therapeutic biologics company, t...

Seeking Alpha - 2 months ago

MiMedx Group, Inc. (MDXG) CEO Tim Wright on Q3 2020 Results - Earnings Call Transcript

GlobeNewsWire - 2 months ago

Third Quarter Net Sales of $64 . 3 M illion , Above Preliminary Range

GlobeNewsWire - 2 months ago

MARIETTA, Ga., Nov. 03, 2020 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (OTC PINK: MDXG) (“MiMedx” or the “Company”), an industry leader in advanced wound care and a therapeutic biologics company,...

GlobeNewsWire - 2 months ago

Only Amniotic Product Covered Under Updated Commercial Policy

GlobeNewsWire - 2 months ago

MARIETTA, Ga., Oct. 30, 2020 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (OTC PINK: MDXG) (“MiMedx” or the “Company”), an industry leader in advanced wound care and a therapeutic biologics company,...

GlobeNewsWire - 2 months ago

MARIETTA, Ga., Oct. 29, 2020 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (OTC PINK: MDXG) (“MiMedx” or the “Company”), an industry leader in advanced wound care and a therapeutic biologics company,...

GlobeNewsWire - 3 months ago

MARIETTA, Ga., Oct. 15, 2020 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (OTC PINK: MDXG) (“MiMedx” or “the Company”), an industry leader in advanced wound care and a therapeutic biologics company,...

GlobeNewsWire - 4 months ago

Research Advances Understanding of Amniotic Tissue as Potential Unique Treatment for Painful Chronic Condition that Affects 242 Million People Globally

GlobeNewsWire - 4 months ago

Third Quarter 2020 Net Sales Expected to be Between $61 Million - $64 Million

GlobeNewsWire - 4 months ago

Research in Plantar Fasciitis Advances Understanding of Amniotic Tissue as Potential Treatment for Chronic Musculoskeletal Pain and Function Disorders

GlobeNewsWire - 4 months ago

New Allograft Expands to Twice its Size and Provides a Protective Structure to Support the Wound Healing Cascade

GlobeNewsWire - 4 months ago

MARIETTA, Ga., Aug. 24, 2020 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (OTC PINK: MDXG) (“MiMedx” or “the Company”), an industry leader in advanced wound care and an emerging therapeutic biolog...

Seeking Alpha - 5 months ago

MiMedx Group, Inc. (MDXG) CEO Tim Wright on Q2 2020 Results - Earnings Call Transcript

GlobeNewsWire - 5 months ago

Pharmaceutical and Biotech Executive to Focus on Product and Pipeline Development Priorities Pharmaceutical and Biotech Executive to Focus on Product and Pipeline Development Priorities

GlobeNewsWire - 5 months ago

Second Quarter Net Sales of $53.6 million

GlobeNewsWire - 5 months ago

Strategic Leader with Proven Record of Delivering Growth and Business Transformation Strategic Leader with Proven Record of Delivering Growth and Business Transformation

Seeking Alpha - 6 months ago

MiMedx Fixes Cash Concerns With Relisting Right Around The Corner

GlobeNewsWire - 6 months ago

Company Now Caught Up in Financial Reporting

GlobeNewsWire - 6 months ago

Annual Report on Form 10-K includes Audited Financial Results for 2019

GlobeNewsWire - 6 months ago

Equity Financing Led by EW Healthcare Partners and Debt Financing Provided by Hayfin Capital Management

Seeking Alpha - 10 months ago

March Flowers Could Bring MiMedx Showers Of Shareholder Returns

Market Watch - 1 year ago

MiMedx Group Inc. MDXG, +0.08% said Tuesday it has reached a settlement with the Securities and Exchange Commission to resolve a probe of its accounting practices.

Seeking Alpha - 1 year ago

10 Reasons To Buy MiMedx Stock Today

Seeking Alpha - 1 year ago

A timetable of upcoming catalysts points to impressive upside potential by the end of 2019 and the beginning of 2020.

Seeking Alpha - 1 year ago

August starts the watch for restatements of MiMedx's financials possibly right before the company's yet to be scheduled 2019 Annual Meeting.

Seeking Alpha - 1 year ago

The beleaguered company has made significant progress in the last two months to right the ship but the shorts continue to press with a thesis that has drifted substantially.

Seeking Alpha - 1 year ago

The beleaguered company has made significant progress in the last two months to right the ship but the shorts continue to press with a thesis that has drifted substantially.

Seeking Alpha - 1 year ago

The beleaguered company has made significant progress in the last two months to right the ship but the shorts continue to press with a thesis that has drifted substantially.

Seeking Alpha - 1 year ago

Annual meeting on June 17th will be an inflection point for the company with former CEO Petit either embraced or shunned by MiMedx shareholders.

Seeking Alpha - 1 year ago

Strong volume and sustained price action are a great signal for investors for very good reasons.

The Motley Fool - 1 year ago

A new board could signify the start of a turnaround.

Market Watch - 1 year ago

MiMedx Group Inc. said Thursday it would be overhauling its board of directors, a decision the company said it made in cooperation with one of its largest shareholders, Prescience Point Capita...

Benzinga - 1 year ago

MiMedx Group Inc can't seem to leave controversy behind. Even as the company announced the conclusion of an independent audit committee investigation into some of its business practices, a new...

Seeking Alpha - 1 year ago

News about the former CEO Pete Petit is not enough of a reason to justify the recent sell-off in MiMedx stock.

About MDXG

MiMedx Group, a biopharmaceutical company, develops and markets regenerative biologics utilizing human placental tissue allografts with patent-protected processes for various sectors of healthcare. It processes the human placental tissue utilizing its proprietary PURION Process to produce allografts. The company's proprietary processing methodology employs aseptic processing techniques in addition to terminal sterilization. Its biomaterial platform technologies include EpiFix, a semi-permeable protective barrier membrane product used for the tr... [Read more...]

Industry
Medical Devices
CEO
Timothy R. Wright
Employees
696
Stock Exchange
NASDAQ
Ticker Symbol
MDXG
Full Company Profile

Financial Performance

In 2019, MiMedx Group's revenue was $299.26 million, a decrease of -16.67% compared to the previous year's $359.11 million. Losses were -$25.58 million, -14.67% less than in 2018.

Financial Statements